The coverage only includes biotech companies developping therapeutics, we DO NOT COVER: pharma companies, the medtech landscape, nor the associated service companies (CRO, CMO, Drug Discovery, etc…), with few exceptions nevertheless. The early-stage R&D programs of Actelion were put into a new company initially valued at €920M. For example, Timmers sees major innovations on the ADC horizon such as antibodies that are more selective to tumors than current ones and payloads that can overcome drug resistance in cancer. Following a busy year of fundraising via a €215M IPO in April and a €172M share offering in September, the Swiss biotech ADC Therapeutics applied for FDA approval of its lead ADC candidate. Not anywhere, but in Europe. Do you want to join 10 000 subscribers who receive the hottest biotech news in their inbox every Friday (for free)? the US ADC developer Immunomedics for a colossal €17.8B. The ADC market is projected to grow at an estimated 3% per year. Almost 30 percent of private-venture investment originates in the United States. There is strong interest in the ADC space right now and an appreciation by investors for what our technology can bring to the table. on the US Nasdaq in June and rapidly managed to join the billion-euro club. The full report is now available here. However, few European biotechs have pursued investment from China, despite the interest its investors have shown in Europe. Before the acquisition, Actelion was Europe’s largest and most valuable biotech. The company has partnerships with other big pharma such as Novartis, GSK, Roche and Bayer, but as CEO Simon Moroney told us, MorphoSys is now also seeking to develop some of the antibodies on its pipeline on its own. Enjoy! From a geographical standpoint, we found that Europe is increasingly moving at two speeds in biotech activity (Exhibit 2). “I came out with the slogan of the ‘thousand-dollar genome’,” McCooke told me. Reinvent your business. CAR-T This cluster map also shined light on the industry’s possible future directions. European Pharmaceutical Review has been keeping the industry informed for 21 years and continues to bring insights into current and emerging technologies, contributions from recognised figures in the life science community and of course, the latest and most up to date news.To celebrate our success, we will be counting down with our bi-monthly feature: The top 21 that will rank the industry. Its founders have gone on to continue shaking the biotech world. “. Philip, Joachim and the growing team at, "We are building the Next Generation of Digital Media for Biotech", Unfazed by the Covid-19 pandemic, the field of, (ADCs) for cancer seems to be flourishing. We are united by the vision to contribute to a better world through biotechnology. In fact, the United Kingdom has not only played a disproportionate part in multiple technologies and disease areas but also been home to 35 percent of all biotech start-ups in Europe since 2012. We’re good at that in Europe. Learn more about cookies, Opens in new Byondis focuses on developing a payload drug that breaks down much faster in the blood than current payload drugs do, with a half-life of around 20 minutes. “One challenge has been the lack of stability of ADCs in the body because the chemical linker connecting the antibody to the payload discharges the payload prematurely due to chemical interactions in the body,” said Jonas Helma-Smets, co-founder and CSO at the German ADC startup Tubulis. Vifor Pharma inks $340m deal with Angion Biomedica Inc. I came out with the slogan of the ‘thousand-dollar genome’. We’re good at that in Europe.”. These together represent half of the biotech companies in Europe (Exhibit 1). The company has a pipeline of antibody drugs targeting inflammatory and autoimmune disease as well as cancer. After the deal, the company did not fully renounce the spirit of independence that it had shown over the years, having rejected offers from the likes of Elliot Advisors and Shire. After listing on Euronext in 2014, the company went public on the US Nasdaq last year with an, Oxford Nanopore is known for developing a. The company managed to do most of its technology development without the help of any partners. Cellectis and partners gather 4 presentations. In 2017, 25 years after its foundation, the company, — Tremfya, a drug for psoriasis developed with Janssen. The full report is now available here. Its second therapy, for milk allergy, is about to start late-stage clinical development. The company has partnerships with other big pharma such as Novartis, GSK, Roche and Bayer, but as CEO Simon Moroney. In addition, 98 percent of follow-on offerings by European biotechs have been on US rather than European exchanges. 2. to test its lead compound in over 12 different indications, including rheumatoid arthritis, ulcerative colitis and Crohn’s disease. Despite these positive dynamics, the financing gap with US biotechs is growing: they receive almost five times as much private funding as their European counterparts do. “. Cellectis is using its gene editing expertise to develop a new generation of CAR-T that can be sourced from donors. In 2017, 25 years after its foundation, the company launched its first antibody — Tremfya, a drug for psoriasis developed with Janssen. Solexa, founded in 1998, is the company responsible for the development of next-generation sequencing technologies used routinely today in genomics research. Our Insider membership gives you access to exclusive content and other advantages. Deals 8. We own our data and we collect them from corporate or well-trusted sources (e.g. As to why the European ADC scene is thriving, it seems like it’s part of a global acceleration in the technology. If you would like information about this content we will be happy to work with you. Its CEO, Jean-Paul Clozel, previously CEO of Actelion, has stated that his plan for Idorsia is to create another Actelion. A spin-off of University College London, Autolus develops a new, safer generation of, — a technology that has shown unprecedented efficacy in treating certain forms of cancer but can carry life-threatening side effects. Portrait of a “typical” biotech company listed in Europe 9. Our research indicated that three factors make Europe’s biotech market attractive to investors: strong hot spots across geographies, modalities, and therapeutic areas; powerhouse research and industry expertise to support basic science and innovation; and an abundance of high-caliber talent. Given the shortage of experienced talent, biotechs must also be flexible about remote working and comfortable with virtual teams to secure the right people—from beyond Europe as well as within it. Further into the future, ADCs could expand beyond cancer treatment and tackle other conditions such as autoimmune disorders. “It took a number of years to validate our technology and get people to understand how it could solve problems that they couldn’t solve with any other platform,” CEO Edwin Moses told me. Enjoy! Philip, Joachim and the growing team at, "We are building the Next Generation of Digital Media for Biotech", Following the lead of Actelion — which used to be Europe’s largest biotech until its massive €28Bn, in 2017 — the Belgian antibody developer Ablynx was, this year for €3.9Bn. Its CEO and founder, Onno van de Stolpe, who has stayed with the company for almost 20 years, seems to have plans for it to remain independent. Our mission is to help leaders in multiple sectors develop a deeper understanding of the global economy. The latest addition to the billion-euro club is Orchard Therapeutics, which made it to the list after an IPO on the US Nasdaq that put the company’s initial market cap at €1Bn. but we had the idea of developing some completely novel technology where we could make billions of antibodies and fish out the ones we wanted. In a space traditionally dominated by big pharma, European biotechs are starting to move the field forward. Cambridge Antibody Technology, co-founded in 1989 by Sir Greg Winter and David Chiswell, is known for having changed how antibodies are made today. To celebrate the start of a new decade, we’ve gathered the names of the 20 European biotech companies that will be stealing the show in 2020. One reason for the small therapeutic window seen in current ADC drugs concerns the molecules that stick together the antibody and its chemotherapy drug payload, called linkers. Teams must plan ambitiously, execute well, and forge strong relationships with the right stakeholders. “We actually see hardly any toxicity for blood cells, which is the most common toxicity for all other ADC platforms,” noted Timmers. They need to look ahead on, say, a ten-year horizon as they plan how to secure market access and reimbursement.